REGN in the 13F filings
Regeneron Pharmaceuticals · CUSIP 75886F107
- Quarter end
- 31 Dec 2024
- the date the book describes
- Filed
- 5 Nov 2026
- latest of these filings; the earliest 4 Feb 2025
- Managers listing it
- 27
- at least, of 95 tracked, among listed positions
- Comparable managers
- 94
- filed both Q3 2024 and Q4 2024; 23 listed it in both
- Shares listed
- 19,401,580
- combined, among listed positions
- Reported value
- $13.8bn
- combined, at the quarter end
Among the 94 comparable managers: 17 buyers (opened or added shares) and 12 sellers (trimmed or exited), at least, among listed positions. Their net change in shares is not known from listed positions, because at least one of them lists it in only one of the two quarters.
Managers listing REGN in Q4 2024
27 of 27 holders
Largest increases and reductions, by shares
Increases
- T. Rowe Price Associates Incexisting position · 2,085,447 shares now+810,144
- D. E. Shaw & Co.existing position · 500,230 shares now+233,994
- Squarepoint Ops LLCexisting position · 254,579 shares now+213,479
- Voloridge Investment Management LLCnew position · 212,128 shares now+212,128
- AllianceBernstein LPexisting position · 623,156 shares now+43,638
Reductions
- Fidelity (FMR LLC)existing position · 8,199,579 shares now-2,163,122
- Capital World Investorsexisting position · 2,778,980 shares now-1,519,407
- Invesco Ltdexisting position · 864,249 shares now-296,924
- Millennium Management LLCexisting position · 133,507 shares now-67,667
- Man Group PLCexisting position · 36,144 shares now-24,377
New positions and exits
New (1)
Exited (2)
- Capital Research Global Investorswas $678m
- Viking Global Investors LPwas $52m
Ownership over time
Tracked managers listing it, at least.
| Quarter | Holders | Reported value | Buyers | Sellers |
|---|---|---|---|---|
| Q2 2013 | 20 | $8.0bn | n.a. | n.a. |
| Q3 2013 | 19 | $10.8bn | n.a. | n.a. |
| Q4 2013 | 17 | $8.9bn | n.a. | n.a. |
| Q1 2014 | 18 | $8.8bn | n.a. | n.a. |
| Q2 2014 | 20 | $8.4bn | n.a. | n.a. |
| Q3 2014 | 22 | $10.7bn | n.a. | n.a. |
| Q4 2014 | 16 | $12.3bn | n.a. | n.a. |
| Q1 2015 | 18 | $13.2bn | n.a. | n.a. |
| Q2 2015 | 16 | $14.7bn | n.a. | n.a. |
| Q3 2015 | 21 | $12.9bn | n.a. | n.a. |
| Q4 2015 | 20 | $15.3bn | n.a. | n.a. |
| Q1 2016 | 24 | $11.3bn | n.a. | n.a. |
| Q2 2016 | 20 | $10.5bn | n.a. | n.a. |
| Q3 2016 | 18 | $12.0bn | n.a. | n.a. |
| Q4 2016 | 22 | $10.4bn | n.a. | n.a. |
| Q1 2017 | 18 | $10.3bn | n.a. | n.a. |
| Q2 2017 | 23 | $13.6bn | n.a. | n.a. |
| Q3 2017 | 21 | $11.6bn | n.a. | n.a. |
| Q4 2017 | 27 | $9.4bn | n.a. | n.a. |
| Q1 2018 | 27 | $8.5bn | n.a. | n.a. |
| Q2 2018 | 24 | $9.2bn | n.a. | n.a. |
| Q3 2018 | 27 | $10.8bn | n.a. | n.a. |
| Q4 2018 | 28 | $9.9bn | n.a. | n.a. |
| Q1 2019 | 28 | $10.4bn | n.a. | n.a. |
| Q2 2019 | 29 | $8.3bn | n.a. | n.a. |
| Q3 2019 | 24 | $7.1bn | n.a. | n.a. |
| Q4 2019 | 18 | $9.0bn | n.a. | n.a. |
| Q1 2020 | 27 | $13.0bn | n.a. | n.a. |
| Q2 2020 | 23 | $19.8bn | n.a. | n.a. |
| Q3 2020 | 24 | $17.4bn | n.a. | n.a. |
| Q4 2020 | 26 | $15.2bn | n.a. | n.a. |
| Q1 2021 | 22 | $13.7bn | n.a. | n.a. |
| Q2 2021 | 27 | $15.3bn | n.a. | n.a. |
| Q3 2021 | 26 | $15.5bn | n.a. | n.a. |
| Q4 2021 | 28 | $16.3bn | n.a. | n.a. |
| Q1 2022 | 25 | $19.2bn | n.a. | n.a. |
| Q2 2022 | 26 | $16.5bn | n.a. | n.a. |
| Q3 2022 | 24 | $19.0bn | n.a. | n.a. |
| Q4 2022 | 30 | $20.2bn | n.a. | n.a. |
| Q1 2023 | 32 | $22.3bn | n.a. | n.a. |
| Q2 2023 | 28 | $18.8bn | n.a. | n.a. |
| Q3 2023 | 26 | $21.1bn | n.a. | n.a. |
| Q4 2023 | 35 | $21.9bn | 22 | 14 |
| Q1 2024 | 28 | $23.6bn | 12 | 20 |
| Q2 2024 | 28 | $25.6bn | 15 | 15 |
| Q3 2024 | 31 | $25.0bn | 17 | 15 |
| Q4 2024 | 27 | $13.8bn | 17 | 12 |
| Q1 2025 | 29 | $12.2bn | 20 | 10 |
| Q2 2025 | 32 | $9.3bn | 24 | 10 |
| Q3 2025 | 33 | $10.1bn | 22 | 12 |
| Q4 2025 | 33 | $16.3bn | 20 | 23 |
| Q1 2026 | 24 | $15.2bn | 14 | 26 |
| Q2 2026 | 22 | $10.6bn | 24 | 15 |
Compare with…
Holders over time, buyers and sellers, and the managers holding both, side by side for up to four stocks.
REGN and LLY →REGN and JNJ →REGN and VRTX →Choose a stock to compare with REGN →
How much of the picture this is
A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. It shows no shorts, cash, bonds or performance, and it is never today’s portfolio. Large books are listed to their largest positions, so a manager missing from this table may still hold a small position below that line. These are 95 tracked managers, not the institutional market.
Which funds own REGN, latest filings →Back to the 13F Explorer →